TEL AVIV, Israel, June 4, 2026
Teva Pharmaceutical Industries Ltd. has announced the European launch of AHZANTIVE® (aflibercept), an EMA-approved biosimilar to Eylea®, marking a significant expansion of the company’s growing biosimilars portfolio and strengthening its presence in the ophthalmology market. The launch aligns with Teva’s Pivot to Growth strategy, which focuses on expanding access to high-quality biologic medicines while building a leading global biosimilars business. With the introduction of AHZANTIVE across multiple European countries, Teva is reinforcing its commitment to improving treatment availability for patients suffering from serious retinal diseases while supporting the sustainability of healthcare systems through broader adoption of biosimilar therapies.
Expanding Access to Vision-Saving Biosimilar Treatments
The launch of AHZANTIVE pre-filled syringes commenced in May 2026 across key European markets, including France, Germany, Spain, and the Netherlands, with additional market launches planned throughout the year. AHZANTIVE is approved for the treatment of several serious retinal disorders, including Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). These chronic and progressive eye diseases represent a major cause of visual impairment and blindness worldwide, creating substantial burdens on patients, caregivers, and healthcare providers.
By introducing a high-quality biosimilar alternative, Teva aims to expand treatment options for ophthalmologists while helping healthcare systems manage increasing demand for advanced retinal therapies. The launch follows Teva’s semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG, supporting broader access to aflibercept biosimilar treatments throughout Europe and Israel.
Demonstrating Comparable Safety and Efficacy
Advertisement
AHZANTIVE has been approved as a biosimilar to Eylea based on comprehensive analytical, clinical, and regulatory evaluations demonstrating comparable efficacy, safety, and immunogenicity to the reference product. The European Commission granted approval for AHZANTIVE in 2025 following extensive evidence confirming its similarity to the originator biologic. Biosimilars play a critical role in expanding patient access to advanced biologic therapies while maintaining the same standards of quality, effectiveness, and safety expected from reference medicines.
As demand for retinal disease treatments continues to rise due to aging populations and increasing rates of diabetes, biosimilars such as AHZANTIVE are expected to contribute significantly to healthcare sustainability while ensuring patients receive effective treatment options. The availability of an aflibercept biosimilar may also support earlier treatment initiation and long-term disease management for individuals facing vision-threatening conditions.
Strengthening Teva’s Global Biosimilars Leadership
The launch further solidifies Teva’s position as one of the leading players in the global biosimilars market. The company currently markets 11 biosimilars worldwide and maintains a pipeline of 13 additional biosimilar candidates spanning therapeutic areas including oncology, immunology, ophthalmology, and respiratory medicine. Through strategic partnerships, manufacturing expertise, and strong commercial capabilities, Teva continues to invest in expanding access to biologic medicines for patients across international markets.
The introduction of AHZANTIVE highlights the growing importance of biosimilars in modern healthcare and demonstrates Teva’s long-term commitment to delivering innovative and affordable treatment solutions. As healthcare systems increasingly seek cost-effective alternatives to high-value biologic therapies, the launch of AHZANTIVE represents an important milestone in advancing patient access to ophthalmology treatments while supporting broader adoption of biosimilars across Europe.
Source: Teva press release
